{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:17:06Z","timestamp":1768990626582,"version":"3.49.0"},"publisher-location":"Singapore","reference-count":235,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811602665","type":"print"},{"value":"9789811602672","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-981-16-0267-2_9","type":"book-chapter","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T20:02:36Z","timestamp":1626206556000},"page":"219-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses"],"prefix":"10.1007","author":[{"given":"Tianguang","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasanthanathan","family":"Poongavanam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"9_CR1","unstructured":"International Committee on Taxonomy of Viruses (2020) The ICTV report virus taxonomy: the classification and nomenclature of viruses. Available from: https:\/\/talk.ictvonline.org\/ictv-reports\/ictv_online_report\/ (Accessed 23 October 2020)"},{"key":"9_CR2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3181\/0903-MR-94","volume":"234","author":"PC Woo","year":"2009","unstructured":"Woo PC, Lau SK, Huang Y, Yuen KY (2009) Coronavirus diversity, phylogeny and interspecies jumping. Exp Biol Med 234:1117\u20131127","journal-title":"Exp Biol Med"},{"key":"9_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2307\/1588476","volume":"14","author":"T Estola","year":"1970","unstructured":"Estola T (1970) Coronaviruses, a new group of animal RNA viruses. Avian Dis 14:330\u2013336","journal-title":"Avian Dis"},{"key":"9_CR4","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2307\/1592697","volume":"42","author":"J Fabricant","year":"1998","unstructured":"Fabricant J (1998) The early history of infectious bronchitis. Avian Dis 42:648\u2013650","journal-title":"Avian Dis"},{"issue":"11 Suppl","key":"9_CR5","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1097\/01.inf.0000188166.17324.60","volume":"24","author":"JS Kahn","year":"2005","unstructured":"Kahn JS, McIntosh K (2005) History and recent advances in coronavirus discovery. Pediatr Infect Dis J 24(11 Suppl):S223\u2013S227","journal-title":"Pediatr Infect Dis J"},{"key":"9_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1055\/s-0028-1119811","volume":"30","author":"S Forgie","year":"2009","unstructured":"Forgie S, Marrie TJ (2009) Healthcare-associated atypical pneumonia. Semin Respir Crit Care Med 30:67\u201385","journal-title":"Semin Respir Crit Care Med"},{"key":"9_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12985-017-0896-0","volume":"14","author":"P Liu","year":"2017","unstructured":"Liu P, Shi L, Zhang W, He J, Liu C, Zhao C, Kong SK, Loo JFC, Gu D, Hu L (2017) Prevalence and genetic diversity analysis of human coronaviruses among cross-border children. Virol J 14:230","journal-title":"Virol J"},{"key":"9_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","volume":"100","author":"VM Corman","year":"2018","unstructured":"Corman VM, Muth D, Niemeyer D, Drosten C (2018) Hosts and sources of endemic human coronaviruses. Adv Virus Res 100:163\u2013188","journal-title":"Adv Virus Res"},{"key":"9_CR9","unstructured":"World Health Organization (2003) Summary table of SARS cases by country. 1 November 2002 to 7 August 2003 [EB\/OL]. https:\/\/www.who.int\/csr\/sars\/country\/2003_08_15\/en\/. Accessed 23 Oct 2020"},{"key":"9_CR10","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814\u20131820","journal-title":"N Engl J Med"},{"key":"9_CR11","unstructured":"World Health Organization (2020) MERS situation update in January 2020 [EB\/OL]. http:\/\/www.emro.who.int\/health-topics\/mers-cov\/mers-outbreaks.html. Accessed 23 Oct 2020"},{"key":"9_CR12","doi-asserted-by":"crossref","unstructured":"Hu B, Guo H, Zhou P, Shi ZL (2021) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19:141\u2013154","DOI":"10.1038\/s41579-020-00459-7"},{"key":"9_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008536","volume":"16","author":"D Tang","year":"2020","unstructured":"Tang D, Comish P, Kang R (2020) The hallmarks of COVID-19 disease. PLoS Pathog 16:e1008536","journal-title":"PLoS Pathog"},{"key":"9_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","volume":"91","author":"DS Hui","year":"2020","unstructured":"Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C et al (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 91:264\u2013266","journal-title":"Int J Infect Dis"},{"key":"9_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395:565\u2013574","journal-title":"Lancet"},{"key":"9_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270\u2013273","journal-title":"Nature"},{"key":"9_CR17","unstructured":"World Health Organization (2020) Coronavirus disease (COVID-2019) situation reports [EB\/OL]. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports\/. Accessed 23 Oct 2020"},{"key":"9_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005531","volume":"12","author":"Y Kim","year":"2016","unstructured":"Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, Chang KO, Pedersen NC (2016) Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog 12:e1005531","journal-title":"PLoS Pathog"},{"key":"9_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","volume":"15","author":"A Zumla","year":"2016","unstructured":"Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY (2016) Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 15:327\u2013347","journal-title":"Nat Rev Drug Discov"},{"key":"9_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"AR Fehr","year":"2015","unstructured":"Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282:1\u201323","journal-title":"Methods Mol Biol"},{"key":"9_CR21","doi-asserted-by":"crossref","unstructured":"B\u00e1ez-Santos YM, Mielech AM, Deng X, Baker S, Mesecar AD (2014) Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus. J Virol 88:12511\u201312527","DOI":"10.1128\/JVI.01294-14"},{"key":"9_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.virusres.2014.01.025","volume":"194","author":"AM Mielech","year":"2014","unstructured":"Mielech AM, Chen Y, Mesecar AD, Baker SC (2014) Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities. Virus Res 194:184\u2013190","journal-title":"Virus Res"},{"key":"9_CR23","doi-asserted-by":"crossref","unstructured":"Hulo C, de Castro E, Masson P, Bougueleret L, Bairoch A, Xenarios I, Le Mercier P (2011) ViralZone: a knowledge resource to understand virus diversity. Nucleic Acids Res 39(Database issue):576\u2013582","DOI":"10.1093\/nar\/gkq901"},{"key":"9_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.chom.2012.04.011","volume":"11","author":"L Zhao","year":"2012","unstructured":"Zhao L, Jha BK, Wu A, Elliott R, Ziebuhr J, Gorbalenya AE, Silverman RH, Weiss SR (2012) Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe 11:607\u2013616","journal-title":"Cell Host Microbe"},{"key":"9_CR25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nsmb1123","volume":"13","author":"DR Beniac","year":"2006","unstructured":"Beniac DR, Andonov A, Grudeski E, Booth TF (2006) Architecture of the SARS coronavirus prefusion spike. Nat Struct Mol Biol 13:751\u2013752","journal-title":"Nat Struct Mol Biol"},{"key":"9_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004077","volume":"10","author":"JL Nieto-Torres","year":"2014","unstructured":"Nieto-Torres JL, DeDiego ML, Verdi\u00e1-B\u00e1guena C, Jimenez-Guarde\u00f1o JM, Regla-Nava JA, Fernandez-Delgado R, Casta\u00f1o-Rodriguez C, Alcaraz A, Torres J, Aguilella VM, Enjuanes L (2014) Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog 10:e1004077","journal-title":"PLoS Pathog"},{"key":"9_CR27","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260\u20131263","journal-title":"Science"},{"key":"9_CR28","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1073\/pnas.0809524106","volume":"106","author":"S Belouzard","year":"2009","unstructured":"Belouzard S, Chu VC, Whittaker GR (2009) Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A 106:5871\u20135876","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR29","doi-asserted-by":"crossref","unstructured":"Bosch BJ, van der Zee R, de Haan CA, Rottier PJ (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 77:8801\u20138811","DOI":"10.1128\/JVI.77.16.8801-8811.2003"},{"key":"9_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1083\/jcb.124.1.55","volume":"124","author":"J Krijnse-Locker","year":"1994","unstructured":"Krijnse-Locker J, Ericsson M, Rottier PJ, Griffiths G (1994) Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step. J Cell Biol 124:55\u201370","journal-title":"J Cell Biol"},{"key":"9_CR31","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111:2605\u20132610","journal-title":"Circulation"},{"key":"9_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41577-020-0343-0","volume":"20","author":"LA Teuwen","year":"2020","unstructured":"Teuwen LA, Geldhof V, Pasut A, Carmeliet P (2020) COVID-19: the vasculature unleashed. Nat Rev Immunol 20:389\u2013391","journal-title":"Nat Rev Immunol"},{"key":"9_CR33","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395:1417\u20131418","journal-title":"Lancet"},{"key":"9_CR34","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration, UK (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033\u20131034","journal-title":"Lancet"},{"key":"9_CR35","doi-asserted-by":"crossref","unstructured":"Recovery Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A et al (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384:693\u2013704","DOI":"10.1056\/NEJMoa2021436"},{"key":"9_CR36","doi-asserted-by":"crossref","unstructured":"Eimer J, Vesterbacka J, Svensson AK, Stojanovic B, Wagrell C, S\u00f6nnerborg A, Nowak P (2021) Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. J Intern Med 289:434\u2013436","DOI":"10.1111\/joim.13162"},{"key":"9_CR37","doi-asserted-by":"crossref","unstructured":"Khiali S, Khani E, Entezari-Maleki T (2020) A comprehensive review of tocilizumab in COVID-19 acute respiratory distress syndrome. J Clin Pharmacol 60:1131\u20131146","DOI":"10.1002\/jcph.1693"},{"key":"9_CR38","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.2217\/imt-2020-0136","volume":"12","author":"M Melody","year":"2020","unstructured":"Melody M, Nelson J, Hastings J, Propst J, Smerina M, Mendez J, Guru P (2020) Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. Immunotherapy 12:1121\u20131126","journal-title":"Immunotherapy"},{"key":"9_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.virusres.2017.01.023","volume":"234","author":"CC Posthuma","year":"2017","unstructured":"Posthuma CC, Te Velthuis AJW, Snijder EJ (2017) Nidovirus RNA polymerases: complex enzymes handling exceptional RNA genomes. Virus Res 234:58\u201373","journal-title":"Virus Res"},{"key":"9_CR40","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1126\/science.abb7498","volume":"368","author":"Y Gao","year":"2020","unstructured":"Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, Wang T, Sun Q, Ming Z, Zhang L et al (2020) Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368:779\u2013782","journal-title":"Science"},{"key":"9_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","volume":"584","author":"HS Hillen","year":"2020","unstructured":"Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P (2020) Structure of replicating SARS-CoV-2 polymerase. Nature 584:154\u2013156","journal-title":"Nature"},{"key":"9_CR42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","volume":"182","author":"Q Wang","year":"2020","unstructured":"Wang Q, Wu J, Wang H, Gao Y, Liu Q, Mu A, Ji W, Yan L, Zhu Y, Zhu C et al (2020) Structural basis for RNA replication by the SARS-CoV-2 polymerase. Cell 182:417\u2013428","journal-title":"Cell"},{"key":"9_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003565","volume":"9","author":"EC Smith","year":"2013","unstructured":"Smith EC, Blanc H, Vignuzzi M, Denison MR (2013) Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 9:e1003565","journal-title":"PLoS Pathog"},{"key":"9_CR44","doi-asserted-by":"crossref","unstructured":"Ogando NS, Zevenhoven-Dobbe JC, van der Meer Y, Bredenbeek PJ, Posthuma CC, Snijder EJ (2020) The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2. J Virol 94:e01246-20","DOI":"10.1128\/JVI.01246-20"},{"key":"9_CR45","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","volume":"11","author":"A Shannon","year":"2020","unstructured":"Shannon A, Selisko B, Le NT, Huchting J, Touret F, Piorkowski G, Fattorini V, Ferron F, Decroly E, Meier C et al (2020) Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun 11:4682","journal-title":"Nat Commun"},{"key":"9_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104899","volume":"182","author":"E Konkolova","year":"2020","unstructured":"Konkolova E, Dejmek M, H\u0159ebabeck\u00fd H, \u0160\u00e1la M, B\u00f6serle J, Nencka R, Boura E (2020) Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses. Antiviral Res 182:104899","journal-title":"Antiviral Res"},{"key":"9_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep43395","volume":"7","author":"MK Lo","year":"2017","unstructured":"Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D, Clarke MO et al (2017) GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci Rep 7:43395","journal-title":"Sci Rep"},{"key":"9_CR48","doi-asserted-by":"crossref","unstructured":"Malin JJ, Su\u00e1rez I, Priesner V, F\u00e4tkenheuer G, Rybniker J (2020) Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev 34:e00162-20","DOI":"10.1128\/CMR.00162-20"},{"key":"9_CR49","doi-asserted-by":"publisher","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I et al (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9:eaal3653","journal-title":"Sci Transl Med"},{"key":"9_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269\u2013271","journal-title":"Cell Res"},{"key":"9_CR51","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, G\u00f6tte M (2020) Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 295:6785\u20136797","journal-title":"J Biol Chem"},{"key":"9_CR52","doi-asserted-by":"crossref","unstructured":"Tchesnokov EP, Gordon CJ, Woolner E, Kocincova D, Perry JK, Feng JY, Porter DP, G\u00f6tte M (2020) Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J Biol Chem 295:16156\u201316165","DOI":"10.1074\/jbc.AC120.015720"},{"key":"9_CR53","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1126\/science.abc1560","volume":"368","author":"W Yin","year":"2020","unstructured":"Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, Wang X, Zhou F, Zhao W, Gao M et al (2020) Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368:1499\u20131504","journal-title":"Science"},{"key":"9_CR54","doi-asserted-by":"crossref","unstructured":"Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R et al (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9:e00221-18","DOI":"10.1128\/mBio.00221-18"},{"key":"9_CR55","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1128\/JVI.00080-16","volume":"90","author":"NR Sexton","year":"2016","unstructured":"Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR (2016) Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. J Virol 90:7415\u20137428","journal-title":"J Virol"},{"key":"9_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104793","volume":"178","author":"A Shannon","year":"2020","unstructured":"Shannon A, Le NT, Selisko B, Eydoux C, Alvarez K, Guillemot JC, Decroly E, Peersen O, Ferron F, Canard B (2020) Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites. Antiviral Res 178:104793","journal-title":"Antiviral Res"},{"key":"9_CR57","doi-asserted-by":"publisher","unstructured":"Martinot M, Jary A, Fafi-Kremer S, Leducq V, Delagreverie H, Garnier M, Pacanowski J, M\u00e9kinian A, Pirenne F, Tiberghien P et al (2020) Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1474","DOI":"10.1093\/cid\/ciaa1474"},{"key":"9_CR58","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(18)33011-3","volume":"392","author":"E Nakkazi","year":"2018","unstructured":"Nakkazi E (2018) Randomised controlled trial begins for Ebola therapeutics. Lancet 392:2338","journal-title":"Lancet"},{"key":"9_CR59","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1922083117","volume":"117","author":"E de Wit","year":"2020","unstructured":"de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H (2020) Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 117:6771\u20136776","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","volume":"585","author":"BN Williamson","year":"2020","unstructured":"Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, van Doremalen N, Leighton I, Yinda CK, P\u00e9rez-P\u00e9rez L et al (2020) Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 585:273\u2013276","journal-title":"Nature"},{"key":"9_CR61","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q et al (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569\u20131578","journal-title":"Lancet"},{"key":"9_CR62","unstructured":"United States Food and Drug Administration (2020). https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed 27 Oct 2020"},{"key":"9_CR63","doi-asserted-by":"crossref","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S et al (2020) Remdesivir for the treatment of Covid-19 \u2013 final report. N Engl J Med 383:1813\u20131826","DOI":"10.1056\/NEJMoa2007764"},{"key":"9_CR64","doi-asserted-by":"crossref","unstructured":"Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG et al (2020) Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 383:1827\u20131837","DOI":"10.1056\/NEJMoa2015301"},{"key":"9_CR65","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","volume":"11","author":"VC Yan","year":"2020","unstructured":"Yan VC, Muller FL (2020) Advantages of the parent nucleoside GS-441524 over remdesivir for Covid-19 treatment. ACS Med Chem Lett 11:1361\u20131366","journal-title":"ACS Med Chem Lett"},{"key":"9_CR66","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446\u2013454","journal-title":"Antiviral Res"},{"key":"9_CR67","doi-asserted-by":"crossref","unstructured":"Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, Hens B, Vergote V, Heylen E, Barthelemy K et al (2020) Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A 117:26955\u201326965","DOI":"10.1073\/pnas.2014441117"},{"key":"9_CR68","doi-asserted-by":"crossref","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 6:1192\u20131198","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"9_CR69","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s13054-020-03137-5","volume":"24","author":"H Yamamura","year":"2020","unstructured":"Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S (2020) Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Crit Care 24:413","journal-title":"Crit Care"},{"key":"9_CR70","doi-asserted-by":"crossref","unstructured":"Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T et al (2020) A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother 64:e01897-20","DOI":"10.1128\/AAC.01897-20"},{"key":"9_CR71","unstructured":"TASS Russian News Agency (2020). https:\/\/tass.ru\/press\/10057. Accessed 27 Oct 2020"},{"key":"9_CR72","doi-asserted-by":"crossref","unstructured":"Chien M, Anderson TK, Jockusch S, Tao C, Li X, Kumar S, Russo JJ, Kirchdoerfer RN, Ju J (2020) Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J Proteome Res 19:4690\u20134697","DOI":"10.1021\/acs.jproteome.0c00392"},{"key":"9_CR73","doi-asserted-by":"publisher","first-page":"104857","DOI":"10.1016\/j.antiviral.2020.104857","volume":"180","author":"S Jockusch","year":"2020","unstructured":"Jockusch S, Tao C, Li X, Anderson TK, Chien M, Kumar S, Russo JJ, Kirchdoerfer RN, Ju J (2020) A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Res 180:104857","journal-title":"Antiviral Res"},{"key":"9_CR74","doi-asserted-by":"publisher","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","volume":"64","author":"S Jeon","year":"2020","unstructured":"Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S (2020) Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother 64:e00819-20","journal-title":"Antimicrob Agents Chemother"},{"key":"9_CR75","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","volume":"586","author":"L Riva","year":"2020","unstructured":"Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, Burgstaller-Muehlbacher S, De Jesus PD, Teriete P, Hull MV et al (2020) Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586:113\u2013119","journal-title":"Nature"},{"key":"9_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70143-6","volume":"10","author":"F Touret","year":"2020","unstructured":"Touret F, Gilles M, Barral K, Nougair\u00e8de A, van Helden J, Decroly E, de Lamballerie X, Coutard B (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep 10:13093","journal-title":"Sci Rep"},{"key":"9_CR77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.coviro.2019.04.002","volume":"35","author":"AJ Pruijssers","year":"2019","unstructured":"Pruijssers AJ, Denison MR (2019) Nucleoside analogues for the treatment of coronavirus infections. Curr Opin Virol 35:57\u201362","journal-title":"Curr Opin Virol"},{"key":"9_CR78","doi-asserted-by":"publisher","first-page":"e01348","DOI":"10.1128\/JVI.01348-19","volume":"93","author":"ML Agostini","year":"2019","unstructured":"Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, Bluemling GR, Lockwood MA, Sheahan TP, Sims AC et al (2019) Small-molecule antiviral \u03b2-D-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol 93:e01348-19","journal-title":"J Virol"},{"key":"9_CR79","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/095632020401500102","volume":"15","author":"DL Barnard","year":"2004","unstructured":"Barnard DL, Hubbard VD, Burton J, Smee DF, Morrey JD, Otto MJ, Sidwell RW (2004) Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and \u03b2-D-N4-hydroxycytidine. Antivir Chem Chemother 15:15\u201322","journal-title":"Antivir Chem Chemother"},{"key":"9_CR80","doi-asserted-by":"crossref","unstructured":"Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Sch\u00e4fer A, Dinnon KH 3rd, Stevens LJ et al (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 12:eabb5883","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"9_CR81","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.cell.2020.07.033","volume":"182","author":"J Chen","year":"2020","unstructured":"Chen J, Malone B, Llewellyn E, Grasso M, Shelton PMM, Olinares PDB, Maruthi K, Eng ET, Vatandaslar H, Chait BT et al (2020) Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex. Cell 182:1560\u20131573","journal-title":"Cell"},{"key":"9_CR82","doi-asserted-by":"crossref","unstructured":"Adedeji AO, Singh K, Kassim A, Coleman CM, Elliott R, Weiss SR, Frieman MB, Sarafianos SG (2014) Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob Agents Chemother 58:4894\u20134898","DOI":"10.1128\/AAC.02994-14"},{"key":"9_CR83","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1016\/j.ejmech.2011.09.005","volume":"46","author":"MK Kim","year":"2011","unstructured":"Kim MK, Yu MS, Park HR, Kim KB, Lee C, Cho SY, Kang J, Yoon H, Kim DE, Choo H, Jeong YJ, Chong Y (2011) 2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV). Eur J Med Chem 46:5698\u20135704","journal-title":"Eur J Med Chem"},{"key":"9_CR84","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.chembiol.2005.01.006","volume":"12","author":"JA Tanner","year":"2005","unstructured":"Tanner JA, Zheng BJ, Zhou J, Watt RM, Jiang JQ, Wong KL, Lin YP, Lu LY, He ML, Kung HF, Kesel AJ, Huang JD (2005) The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol 12:303\u2013311","journal-title":"Chem Biol"},{"key":"9_CR85","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41564-020-00802-x","volume":"5","author":"S Yuan","year":"2020","unstructured":"Yuan S, Wang R, Chan JF, Zhang AJ, Cheng T, Chik KK, Ye ZW, Wang S, Lee AC, Jin L et al (2020) Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol 5:1439\u20131448","journal-title":"Nat Microbiol"},{"key":"9_CR86","doi-asserted-by":"publisher","first-page":"8416","DOI":"10.1093\/nar\/gkv838","volume":"43","author":"KC Lehmann","year":"2015","unstructured":"Lehmann KC, Gulyaeva A, Zevenhoven-Dobbe JC, Janssen GM, Ruben M, Overkleeft HS, van Veelen PA, Samborskiy DV, Kravchenko AA, Leontovich AM et al (2015) Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. Nucleic Acids Res 43:8416\u20138434","journal-title":"Nucleic Acids Res"},{"key":"9_CR87","doi-asserted-by":"crossref","unstructured":"Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F et al (2014) Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 5:3067","DOI":"10.1038\/ncomms4067"},{"key":"9_CR88","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1128\/JVI.02322-09","volume":"84","author":"BR O'Keefe","year":"2010","unstructured":"O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, Palmer KE, Barnett BW, Meyerholz DK, Wohlford-Lenane CL, McCray PB Jr (2010) Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol 84:2511\u20132521","journal-title":"J Virol"},{"key":"9_CR89","doi-asserted-by":"publisher","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","volume":"5","author":"S Xia","year":"2019","unstructured":"Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA et al (2019) A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv 5:eaav4580","journal-title":"Sci Adv"},{"key":"9_CR90","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"S Xia","year":"2020","unstructured":"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S et al (2020) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30:343\u2013355","journal-title":"Cell Res"},{"key":"9_CR91","doi-asserted-by":"publisher","first-page":"e00635","DOI":"10.1128\/JVI.00635-20","volume":"94","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Yu D, Yan H, Chong H, He Y (2020) Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity. J Virol 94:e00635-20","journal-title":"J Virol"},{"key":"9_CR92","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","volume":"6","author":"X Wang","year":"2020","unstructured":"Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X et al (2020) The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 6:28","journal-title":"Cell Discov"},{"key":"9_CR93","doi-asserted-by":"crossref","unstructured":"Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z (2021) Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Med Virol 93:481\u2013490","DOI":"10.1002\/jmv.26256"},{"key":"9_CR94","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021402","volume":"99","author":"X Wang","year":"2020","unstructured":"Wang X, Xie P, Sun G, Zhao M, Deng Z, Zhou Y, Bao S (2020) A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019. Medicine 99:e21402","journal-title":"Medicine"},{"key":"9_CR95","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2019.1581171","volume":"14","author":"AL Totura","year":"2019","unstructured":"Totura AL, Bavari S (2019) Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discovery 14:397\u2013412","journal-title":"Expert Opin Drug Discovery"},{"key":"9_CR96","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/infdis\/jit609","volume":"209","author":"S Agnihothram","year":"2014","unstructured":"Agnihothram S, Gopal R, Yount BL Jr, Donaldson EF, Menachery VD, Graham RL, Scobey TD, Gralinski LE, Denison MR, Zambon M, Baric RS (2014) Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis 209:995\u20131006","journal-title":"J Infect Dis"},{"key":"9_CR97","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","volume":"9","author":"X Tian","year":"2020","unstructured":"Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, Ying T (2020) Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 9:382\u2013385","journal-title":"Emerg Microbes Infect"},{"key":"9_CR98","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","volume":"27","author":"J Huo","year":"2020","unstructured":"Huo J, Le Bas A, Ruza RR, Duyvesteyn HME, Mikolajek H, Malinauskas T, Tan TK, Rijal P, Dumoux M, Ward PN et al (2020) Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol 27:846\u2013854","journal-title":"Nat Struct Mol Biol"},{"key":"9_CR99","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L et al (2020) A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584:120\u2013124","journal-title":"Nature"},{"key":"9_CR100","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K et al (2020) Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369:1010\u20131014","journal-title":"Science"},{"key":"9_CR101","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M et al (2020) Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369:1014\u20131018","journal-title":"Science"},{"key":"9_CR102","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.09.007","volume":"183","author":"W Li","year":"2020","unstructured":"Li W, Sch\u00e4fer A, Kulkarni SS, Liu X, Martinez DR, Chen C, Sun Z, Leist SR, Drelich A, Zhang L et al (2020) High potency of a bivalent human VH domain in SARS-CoV-2 animal models. Cell 183:429\u2013441","journal-title":"Cell"},{"key":"9_CR103","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","volume":"181","author":"D Kim","year":"2020","unstructured":"Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H (2020) The architecture of SARS-CoV-2 transcriptome. Cell 181:914\u2013921","journal-title":"Cell"},{"key":"9_CR104","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"G Li","year":"2020","unstructured":"Li G, De Clercq E (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 19:149\u2013150","journal-title":"Nat Rev Drug Discov"},{"key":"9_CR105","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F (2020) Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117:11727\u201311734","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR106","doi-asserted-by":"crossref","unstructured":"Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY (2020) Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 9:221\u2013236","DOI":"10.1080\/22221751.2020.1719902"},{"key":"9_CR107","doi-asserted-by":"crossref","unstructured":"Gil C, Ginex T, Maestro I, Nozal V, Barrado-Gil L, Cuesta-Geijo M\u00c1, Urquiza J, Ram\u00edrez D, Alonso C, Campillo NE, Martinez A (2020) COVID-19: drug targets and potential treatments. J Med Chem 63:12359\u201312386","DOI":"10.1021\/acs.jmedchem.0c00606"},{"key":"9_CR108","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C et al (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289\u2013293","journal-title":"Nature"},{"key":"9_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127377","volume":"30","author":"S Ullrich","year":"2020","unstructured":"Ullrich S, Nitsche C (2020) The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett 30:127377","journal-title":"Bioorg Med Chem Lett"},{"key":"9_CR110","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459\u2013468","journal-title":"Nature"},{"key":"9_CR111","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1038\/s41467-020-17189-2","volume":"11","author":"S Sadegh","year":"2020","unstructured":"Sadegh S, Matschinske J, Blumenthal DB, Galindez G, Kacprowski T, List M, Nasirigerdeh R, Oubounyt M, Pichlmair A, Rose TD et al (2020) Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing. Nat Commun 11:3518","journal-title":"Nat Commun"},{"key":"9_CR112","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","volume":"41","author":"MP Lythgoe","year":"2020","unstructured":"Lythgoe MP, Middleton P (2020) Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci 41:363\u2013382","journal-title":"Trends Pharmacol Sci"},{"key":"9_CR113","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1111\/febs.12936","volume":"281","author":"R Hilgenfeld","year":"2014","unstructured":"Hilgenfeld R (2014) From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 281:4085\u20134096","journal-title":"FEBS J"},{"key":"9_CR114","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","volume":"368","author":"W Dai","year":"2020","unstructured":"Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F et al (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368:1331\u20131335","journal-title":"Science"},{"key":"9_CR115","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","volume":"3","author":"H Yang","year":"2005","unstructured":"Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, Zhao Q, Zhou Z, Pei D, Ziebuhr J et al (2005) Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 3:e324","journal-title":"PLoS Biol"},{"key":"9_CR116","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science 368:409\u2013412","journal-title":"Science"},{"key":"9_CR117","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41401-020-0483-6","volume":"41","author":"HX Su","year":"2020","unstructured":"Su HX, Yao S, Zhao WF, Li MJ, Liu J, Shang WJ, Xie H, Ke CQ, Hu HC, Gao MN et al (2020) Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 41:1167\u20131177","journal-title":"Acta Pharmacol Sin"},{"key":"9_CR118","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","volume":"30","author":"C Ma","year":"2020","unstructured":"Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y, Wang J (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 30:678\u2013692","journal-title":"Cell Res"},{"key":"9_CR119","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","volume":"115","author":"YM Baez-Santos","year":"2015","unstructured":"Baez-Santos YM, St John SE, Mesecar AD (2015) The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res 115:21\u201338","journal-title":"Antiviral Res"},{"key":"9_CR120","doi-asserted-by":"publisher","first-page":"16119","DOI":"10.1073\/pnas.0805240105","volume":"105","author":"K Ratia","year":"2008","unstructured":"Ratia K, Pegan S, Takayama J, Sleeman K, Coughlin M, Baliji S, Chaudhuri R, Fu W, Prabhakar BS, Johnson ME et al (2008) A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A 105:16119\u201316124","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR121","doi-asserted-by":"publisher","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","volume":"6","author":"W Rut","year":"2020","unstructured":"Rut W, Lv Z, Zmudzinski M, Patchett S, Nayak D, Snipas SJ, El Oualid F, Huang TT, Bekes M, Drag M et al (2020) Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design. Sci Adv 6:eabd4596","journal-title":"Sci Adv"},{"key":"9_CR122","doi-asserted-by":"publisher","first-page":"eabc5332","DOI":"10.1126\/scitranslmed.abc5332","volume":"12","author":"AD Rathnayake","year":"2020","unstructured":"Rathnayake AD, Zheng J, Kim Y, Perera KD, Mackin S, Meyerholz DK, Kashipathy MM, Battaile KP, Lovell S, Perlman S et al (2020) 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. Sci Transl Med 12:eabc5332","journal-title":"Sci Transl Med"},{"key":"9_CR123","doi-asserted-by":"crossref","unstructured":"Hattori SI, Higshi-Kuwata N, Raghavaiah J, Das D, Bulut H, Davis DA, Takamatsu Y, Matsuda K, Takamune N, Kishimoto N et al (2020) GRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infection. MBio 11:e01833-20","DOI":"10.1128\/mBio.01833-20"},{"key":"9_CR124","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106275","volume":"39","author":"T Klemm","year":"2020","unstructured":"Klemm T, Ebert G, Calleja DJ, Allison CC, Richardson LW, Bernardini JP, Lu BG, Kuchel NW, Grohmann C, Shibata Y et al (2020) Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO J 39:e106275","journal-title":"EMBO J"},{"key":"9_CR125","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450\u2013454","journal-title":"Nature"},{"key":"9_CR126","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581:215\u2013220","journal-title":"Nature"},{"key":"9_CR127","doi-asserted-by":"publisher","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","volume":"291","author":"N Zhou","year":"2016","unstructured":"Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, Huang F, Peng T, Zhang J, Liu C et al (2016) Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome\/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 291:9218\u20139232","journal-title":"J Biol Chem"},{"key":"9_CR128","doi-asserted-by":"crossref","unstructured":"Zhuang MW, Cheng Y, Zhang J, Jiang XM, Wang L, Deng J, Wang PH (2020) Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection. J Med Virol 92:2693\u20132701","DOI":"10.1002\/jmv.26139"},{"key":"9_CR129","doi-asserted-by":"publisher","first-page":"11852","DOI":"10.1021\/ja0277226","volume":"124","author":"NA Dales","year":"2002","unstructured":"Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, Gavin JM, Hales P, Kaushik VK, Stewart M et al (2002) Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 124:11852\u201311853","journal-title":"J Am Chem Soc"},{"key":"9_CR130","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1161\/01.HYP.0000146120.29648.36","volume":"44","author":"MJ Huentelman","year":"2004","unstructured":"Huentelman MJ, Zubcevic J, Hern\u00e1ndez Prada JA, Xiao X, Dimitrov DS, Raizada MK, Ostrov DA (2004) Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension 44:903\u2013906","journal-title":"Hypertension"},{"key":"9_CR131","doi-asserted-by":"crossref","unstructured":"Olaleye OA, Kaur M, Onyenaka C, Adebusuyi T (2021) Discovery of clioquinol and analogues as novel inhibitors of severe acute respiratory syndrome coronavirus 2 infection, ACE2 and ACE2 \u2013 spike protein interaction in vitro. Helyon 7:e6426","DOI":"10.1016\/j.heliyon.2021.e06426"},{"key":"9_CR132","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1021\/cc0500607","volume":"7","author":"H Hu","year":"2005","unstructured":"Hu H, Li L, Kao RY, Kou B, Wang Z, Zhang L, Zhang H, Hao Z, Tsui WH, Ni A et al (2005) Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. J Comb Chem 7:648\u2013656","journal-title":"J Comb Chem"},{"key":"9_CR133","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.virol.2006.01.029","volume":"350","author":"DP Han","year":"2006","unstructured":"Han DP, Penn-Nicholson A, Cho MW (2006) Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology 350:15\u201325","journal-title":"Virology"},{"key":"9_CR134","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.antiviral.2011.12.012","volume":"94","author":"AW Struck","year":"2012","unstructured":"Struck AW, Axmann M, Pfefferle S, Drosten C, Meyer B (2012) A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2. Antiviral Res 94:288\u2013296","journal-title":"Antiviral Res"},{"key":"9_CR135","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/path.1597","volume":"203","author":"KF To","year":"2004","unstructured":"To KF, Lo AW (2004) Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol 203:740\u2013743","journal-title":"J Pathol"},{"key":"9_CR136","doi-asserted-by":"publisher","first-page":"12658","DOI":"10.1128\/JVI.01542-10","volume":"84","author":"S Matsuyama","year":"2010","unstructured":"Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F (2010) Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol 84:12658\u201312664","journal-title":"J Virol"},{"key":"9_CR137","doi-asserted-by":"crossref","unstructured":"Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M et al (2020) Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370:856\u2013860","DOI":"10.1126\/science.abd2985"},{"key":"9_CR138","doi-asserted-by":"publisher","first-page":"8722","DOI":"10.1128\/JVI.00253-07","volume":"81","author":"Y Inoue","year":"2007","unstructured":"Inoue Y, Tanaka N, Tanaka Y, Inoue S, Morita K, Zhuang M, Hattori T, Sugamura K (2007) Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J Virol 81:8722\u20138729","journal-title":"J Virol"},{"key":"9_CR139","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1128\/JVI.02232-10","volume":"85","author":"I Glowacka","year":"2011","unstructured":"Glowacka I, Bertram S, M\u00fcller MA, Allen P, Soilleux E, Pfefferle S, Steffen I, Tsegaye TS, He Y, Gnirss K et al (2011) Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 85:4122\u20134134","journal-title":"J Virol"},{"key":"9_CR140","doi-asserted-by":"publisher","first-page":"12543","DOI":"10.1073\/pnas.0503203102","volume":"102","author":"S Matsuyama","year":"2005","unstructured":"Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F (2005) Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci U S A 102:12543\u201312547","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR141","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271\u2013280","journal-title":"Cell"},{"key":"9_CR142","doi-asserted-by":"crossref","unstructured":"Shirato K, Kawase M, Matsuyama S (2013) Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol 87:12552\u201312561","DOI":"10.1128\/JVI.01890-13"},{"key":"9_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108254","volume":"33","author":"YW Cheng","year":"2020","unstructured":"Cheng YW, Chao TL, Li CL, Chiu MF, Kao HC, Wang SH, Pang YH, Lin CH, Tsai YM, Lee WH et al (2020) Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep 33:108254","journal-title":"Cell Rep"},{"key":"9_CR144","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","volume":"116","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, P\u00f6hlmann S, McKerrow JH, Renslo AR, Simmons G (2015) Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 116:76\u201384","journal-title":"Antiviral Res"},{"key":"9_CR145","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Schroeder S, Kleine-Weber H, M\u00fcller MA, Drosten C, P\u00f6hlmann S (2020) Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother 64:e00754-20","DOI":"10.1128\/AAC.00754-20"},{"key":"9_CR146","doi-asserted-by":"crossref","unstructured":"Ko M, Jeon S, Ryu WS, Kim S (2021) Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. J Med Virol 93:1403\u20131408","DOI":"10.1002\/jmv.26397"},{"key":"9_CR147","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14756366.2016.1193732","volume":"31","author":"E P\u00e1szti-Gere","year":"2016","unstructured":"P\u00e1szti-Gere E, Czimmermann E, Ujhelyi G, Balla P, Maiwald A, Steinmetzer T (2016) In vitro characterization of TMPRSS2 inhibition in IPEC-J2 cells. J Enzyme Inhib Med Chem 31:123\u2013129","journal-title":"J Enzyme Inhib Med Chem"},{"key":"9_CR148","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1515\/BC.2004.040","volume":"385","author":"A Rossi","year":"2004","unstructured":"Rossi A, Deveraux Q, Turk B, Sali A (2004) Comprehensive search for cysteine cathepsins in the human genome. Biol Chem 385:363\u2013372","journal-title":"Biol Chem"},{"key":"9_CR149","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1073\/pnas.0505577102","volume":"102","author":"G Simmons","year":"2005","unstructured":"Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A 102:11876\u201311881","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR150","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.antiviral.2013.09.028","volume":"100","author":"G Simmons","year":"2013","unstructured":"Simmons G, Zmora P, Gierer S, Heurich A, P\u00f6hlmann S (2013) Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res 100:605\u2013614","journal-title":"Antiviral Res"},{"key":"9_CR151","doi-asserted-by":"crossref","unstructured":"Shah PP, Wang T, Kaletsky RL, Myers MC, Purvis JE, Jing H, Huryn DM, Greenbaum DC, Smith AB 3rd, Bates P, Diamond SL (2010) A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Mol Pharmacol 78:319\u2013324","DOI":"10.1124\/mol.110.064261"},{"key":"9_CR152","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.virol.2014.07.025","volume":"464","author":"V Shivanna","year":"2014","unstructured":"Shivanna V, Kim Y, Chang K-O (2014) Endosomal acidification and cathepsin L activity is required for calicivirus replication. Virology 464:287\u2013295","journal-title":"Virology"},{"key":"9_CR153","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1110656","volume":"308","author":"K Chandran","year":"2005","unstructured":"Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643\u20131645","journal-title":"Science"},{"key":"9_CR154","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/14787210.2017.1305888","volume":"15","author":"C Salata","year":"2017","unstructured":"Salata C, Calistri A, Parolin C, Baritussio A, Pal\u00f9 G (2017) Antiviral activity of cationic amphiphilic drugs. Expert Rev Anti-Infect Ther 15:483\u2013492","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"9_CR155","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","volume":"3","author":"A Savarino","year":"2003","unstructured":"Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today\u2019s diseases? Lancet Infect Dis 3:722\u2013727","journal-title":"Lancet Infect Dis"},{"key":"9_CR156","doi-asserted-by":"crossref","unstructured":"de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ (2014) Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58:4875\u20134884","DOI":"10.1128\/AAC.03011-14"},{"key":"9_CR157","unstructured":"European Medicines Agency (2020) COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. European Medicines Agency (EMA). 1 April 2020. https:\/\/www.ema.europa.eu\/en\/news\/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes"},{"key":"9_CR158","unstructured":"World Health Organization (2020) Solidarity clinical trial for COVID-19 treatments. https:\/\/www.who.int. Accessed 27 Oct 2020"},{"key":"9_CR159","unstructured":"United States Food and Drug Administration (2020) Coronavirus (COVID-19) update: FDA warns of newly discovered potential drug interaction that may reduce effectiveness of a COVID-19 treatment authorized for emergency use. U.S. Food and Drug Administration (FDA) (Press release). 15 June 2020. Retrieved 15 June 2020. This article incorporates text from this source, which is in the public domain."},{"key":"9_CR160","doi-asserted-by":"crossref","unstructured":"Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, Hensley SE, Gill S, Vogl DT, Maillard I et al (2021) Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med 181:195\u2013202","DOI":"10.1001\/jamainternmed.2020.6319"},{"key":"9_CR161","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","volume":"585","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, M\u00f6sbauer K, Hofmann-Winkler H, Kaul A, Kleine-Weber H, Kr\u00fcger N, Gassen NC, M\u00fcller MA, Drosten C, P\u00f6hlmann S (2020) Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature 585:588\u2013590","journal-title":"Nature"},{"key":"9_CR162","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.gene.2005.10.019","volume":"367","author":"O Cordin","year":"2006","unstructured":"Cordin O, Banroques J, Tanner NK, Linder P (2006) The DEAD-box protein family of RNA helicases. Gene 367:17\u201337","journal-title":"Gene"},{"key":"9_CR163","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev.biophys.37.032807.125908","volume":"37","author":"AM Pyle","year":"2008","unstructured":"Pyle AM (2008) Translocation and unwinding mechanisms of RNA and DNA helicases. Annu Rev Biophys 37:317\u2013336","journal-title":"Annu Rev Biophys"},{"key":"9_CR164","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1515\/BC.2009.135","volume":"390","author":"M Hilbert","year":"2009","unstructured":"Hilbert M, Karow AR, Klostermeier D (2009) The mechanism of ATP-dependent RNA unwinding by DEAD box proteins. Biol Chem 390:1237\u20131250","journal-title":"Biol Chem"},{"key":"9_CR165","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4161\/rna.21966","volume":"10","author":"AZ Andreou","year":"2013","unstructured":"Andreou AZ, Klostermeier D (2013) The DEAD-box helicase eIF4A: paradigm or the odd one out? RNA Biol 10:19\u201332","journal-title":"RNA Biol"},{"key":"9_CR166","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0009-2797(98)00073-8","volume":"115","author":"SK Lee","year":"1998","unstructured":"Lee SK, Cui B, Mehta RR, Kinghorn AD, Pezzuto JM (1998) Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica. Chem Biol Interact 115:215\u2013228","journal-title":"Chem Biol Interact"},{"key":"9_CR167","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.antiviral.2017.12.010","volume":"150","author":"C M\u00fcller","year":"2018","unstructured":"M\u00fcller C, Schulte FW, Lange-Gr\u00fcnweller K, Obermann W, Madhugiri R, Pleschka S, Ziebuhr J, Hartmann RK, Gr\u00fcnweller A (2018) Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses. Antiviral Res 150:123\u2013129","journal-title":"Antiviral Res"},{"key":"9_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/srep35100","volume":"6","author":"A Losada","year":"2016","unstructured":"Losada A, Mu\u00f1oz-Alonso MJ, Garc\u00eda C, S\u00e1nchez-Murcia PA, Mart\u00ednez-Leal JF, Dom\u00ednguez JM, Lillo MP, Gago F, Galmarini CM (2016) Translation elongation factor eEF1A2 is a novel anticancer target for the marine natural product plitidepsin. Sci Rep 6:35100","journal-title":"Sci Rep"},{"issue":"3-4","key":"9_CR169","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.vetmic.2014.05.034","volume":"172","author":"X Zhang","year":"2014","unstructured":"Zhang X, Shi H, Chen J, Shi D, Li C, Feng L (2014) EF1A interacting with nucleocapsid protein of transmissible gastroenteritis coronavirus and plays a role in virus replication. Vet Microbiol 172:443\u2013448","journal-title":"Vet Microbiol"},{"key":"9_CR170","doi-asserted-by":"crossref","unstructured":"Schmidt HR, Kruse AC (2019) The molecular function of \u03c3 receptors: past, present, and future. Trends Pharmacol Sci 40:636\u2013654","DOI":"10.1016\/j.tips.2019.07.006"},{"key":"9_CR171","doi-asserted-by":"crossref","unstructured":"Carelli JD, Sethofer SG, Smith GA, Miller HR, Simard JL, Merrick WC, Jain RK, Ross NT, Taunton J (2015) Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex. Elife 4:e10222","DOI":"10.7554\/eLife.10222"},{"key":"9_CR172","doi-asserted-by":"publisher","first-page":"33035","DOI":"10.1074\/jbc.R400007200","volume":"32","author":"DR Evans","year":"2004","unstructured":"Evans DR, Guy HI (2004) Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem 32:33035\u201333038","journal-title":"J Biol Chem"},{"key":"9_CR173","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.abb.2017.06.019","volume":"632","author":"RAG Reis","year":"2017","unstructured":"Reis RAG, Calil FA, Feliciano PR, Pinheiro MP, Nonato MC (2017) The dihydroorotate dehydrogenases: past and present. Arch Biochem Biophys 632:175\u2013191","journal-title":"Arch Biochem Biophys"},{"key":"9_CR174","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1128\/AAC.00282-16","volume":"60","author":"DH Chung","year":"2016","unstructured":"Chung DH, Golden JE, Adcock RS, Schroeder CE, Chu YK, Sotsky JB, Cramer DE, Chilton PM, Song C, Anantpadma M et al (2016) Discovery of a broad-spectrum antiviral compound that inhibits pyrimidine biosynthesis and establishes a type 1 interferon-independent antiviral state. Antimicrob Agents Chemother 60:4552\u20134562","journal-title":"Antimicrob Agents Chemother"},{"key":"9_CR175","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1073\/pnas.1101143108","volume":"14","author":"HH Hoffmann","year":"2011","unstructured":"Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML (2011) Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A 14:5777\u20135782","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR176","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.antiviral.2018.08.012","volume":"158","author":"P Luthra","year":"2018","unstructured":"Luthra P, Naidoo J, Pietzsch CA, De S, Khadka S, Anantpadma M, Williams CG, Edwards MR, Davey RA, Bukreyev A et al (2018) Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses. Antiviral Res 158:288\u2013302","journal-title":"Antiviral Res"},{"key":"9_CR177","doi-asserted-by":"publisher","first-page":"6548","DOI":"10.1128\/JVI.02510-10","volume":"85","author":"QY Wang","year":"2011","unstructured":"Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, Zhou J, Poh MK, Florez de Sessions P, Niyomrattanakit P et al (2011) Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 85:6548\u20136556","journal-title":"J Virol"},{"key":"9_CR178","doi-asserted-by":"publisher","first-page":"124","DOI":"10.7326\/0003-4819-148-2-200801150-00192","volume":"148","author":"KE Donahue","year":"2008","unstructured":"Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124\u2013134","journal-title":"Ann Intern Med"},{"key":"9_CR179","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","volume":"11","author":"R Xiong","year":"2020","unstructured":"Xiong R, Zhang L, Li S, Sun Y, Ding M, Wang Y, Zhao Y, Wu Y, Shang W, Jiang X et al (2020) Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell 11:723\u2013739","journal-title":"Protein Cell"},{"key":"9_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100719","volume":"53","author":"S Dro\u017cd\u017cal","year":"2020","unstructured":"Dro\u017cd\u017cal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, \u0141os MJ (2020) FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat 53:100719","journal-title":"Drug Resist Updat"},{"key":"9_CR181","doi-asserted-by":"crossref","unstructured":"Luban J, Sattler R, M\u00fchlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C et al (2021) The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Res 292:198246","DOI":"10.1016\/j.virusres.2020.198246"},{"key":"9_CR182","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.virusres.2014.02.010","volume":"184","author":"J Carbajo-Lozoya","year":"2014","unstructured":"Carbajo-Lozoya J, Ma-Lauer Y, Male\u0161evi\u0107 M, Theuerkorn M, Kahlert V, Prell E, von Brunn B, Muth D, Baumert TF, Drosten C et al (2014) Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including alisporivir. Virus Res 184:44\u201353","journal-title":"Virus Res"},{"key":"9_CR183","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/hep.27960","volume":"62","author":"JM Pawlotsky","year":"2015","unstructured":"Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR, Shah S, Wedemeyer H et al (2015) Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology 62:1013\u20131023","journal-title":"Hepatology"},{"key":"9_CR184","doi-asserted-by":"crossref","unstructured":"Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM et al (2020) Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor alisporivir (Debio 025). Antimicrob Agents Chemother 64:e00876-20","DOI":"10.1128\/AAC.00876-20"},{"key":"9_CR185","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.coviro.2011.11.001","volume":"1","author":"DE Levy","year":"2011","unstructured":"Levy DE, Mari\u00e9 IJ, Durbin JE (2011) Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 1:476\u2013486","journal-title":"Curr Opin Virol"},{"key":"9_CR186","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481\u2013485","journal-title":"Nature"},{"key":"9_CR187","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14:36\u201349","journal-title":"Nat Rev Immunol"},{"key":"9_CR188","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark GR, Darnell JE Jr (2012) The JAK-STAT pathway at twenty. Immunity 36:503\u2013514","journal-title":"Immunity"},{"key":"9_CR189","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012697","volume":"12","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ, Monteil V, Lauschke VM, Mirazimi A, Youhanna S et al (2020) Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med 12:e12697","journal-title":"EMBO Mol Med"},{"key":"9_CR190","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1517\/14712598.4.6.827","volume":"4","author":"J Cinatl Jr","year":"2004","unstructured":"Cinatl J Jr, Michaelis M, Scholz M, Doerr HW (2004) Role of interferons in the treatment of severe acute respiratory syndrome. Expert Opin Biol Ther 4:827\u2013836","journal-title":"Expert Opin Biol Ther"},{"key":"9_CR191","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/srep01686","volume":"3","author":"D Falzarano","year":"2013","unstructured":"Falzarano D, Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H (2013) Inhibition of novel \u03b2 coronavirus replication by a combination of interferon-\u03b12b and ribavirin. Sci Rep 3:1686","journal-title":"Sci Rep"},{"key":"9_CR192","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.bbrc.2004.11.128","volume":"326","author":"B Morgenstern","year":"2005","unstructured":"Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr (2005) Ribavirin and interferon-\u03b2 synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 326:905\u2013908","journal-title":"Biochem Biophys Res Commun"},{"key":"9_CR193","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","volume":"27","author":"A Park","year":"2020","unstructured":"Park A, Iwasaki A (2020) Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 27:870\u2013878","journal-title":"Cell Host Microbe"},{"key":"9_CR194","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/infdis\/jiaa350","volume":"222","author":"N Clementi","year":"2020","unstructured":"Clementi N, Ferrarese R, Criscuolo E, Diotti RA, Castelli M, Scagnolari C, Burioni R, Antonelli G, Clementi M, Mancini N (2020) Interferon-\u03b2-1a inhibition of severe acute respiratory syndrome-coronavirus 2 in vitro when administered after virus infection. J Infect Dis 222:722\u2013725","journal-title":"J Infect Dis"},{"key":"9_CR195","doi-asserted-by":"publisher","first-page":"13958","DOI":"10.1074\/jbc.AC120.013788","volume":"295","author":"U Felgenhauer","year":"2020","unstructured":"Felgenhauer U, Schoen A, Gad HH, Hartmann R, Schaubmar AR, Failing K, Drosten C, Weber F (2020) Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem 295:13958\u201313964","journal-title":"J Biol Chem"},{"key":"9_CR196","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1185\/030079905X50534","volume":"21","author":"SA Cohen","year":"2005","unstructured":"Cohen SA (2005) Use of nitazoxanide as a new therapeutic option for persistent diarrhea: a pediatric perspective. Curr Med Res Opin 21:999\u20131004","journal-title":"Curr Med Res Opin"},{"key":"9_CR197","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1086\/428839","volume":"40","author":"LM Fox","year":"2005","unstructured":"Fox LM, Saravolatz LD (2005) Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 40:1173\u20131180","journal-title":"Clin Infect Dis"},{"key":"9_CR198","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/AAC.03947-14","volume":"59","author":"G Belardo","year":"2015","unstructured":"Belardo G, Cenciarelli O, La Frazia S, Rossignol JF, Santoro MG (2015) Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrob Agents Chemother 59:1061\u20131069","journal-title":"Antimicrob Agents Chemother"},{"key":"9_CR199","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","volume":"77","author":"BE Korba","year":"2008","unstructured":"Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF (2008) Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 77:56\u201363","journal-title":"Antiviral Res"},{"key":"9_CR200","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/nbt.2391","volume":"30","author":"X Tan","year":"2012","unstructured":"Tan X, Hu L, Luquette LJ 3rd, Gao G, Liu Y, Qu H, Xi R, Lu ZJ, Park PJ, Elledge SJ (2012) Systematic identification of synergistic drug pairs targeting HIV. Nat Biotechnol 30:1125\u20131130","journal-title":"Nat Biotechnol"},{"key":"9_CR201","doi-asserted-by":"publisher","first-page":"387","DOI":"10.5414\/CPP38387","volume":"38","author":"J Broekhuysen","year":"2000","unstructured":"Broekhuysen J, Stockis A, Lins RL, De JG, Rossignol JF (2000) Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 38:387\u2013394","journal-title":"Int J Clin Pharmacol Ther"},{"key":"9_CR202","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","volume":"9","author":"J-F Rossignol","year":"2016","unstructured":"Rossignol J-F (2016) Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 9:227\u2013230","journal-title":"J Infect Public Health"},{"key":"9_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104615","volume":"172","author":"MP Thom\u00e9","year":"2019","unstructured":"Thom\u00e9 MP, Borde C, Larsen AK, Henriques JAP, Lenz G, Escargueil AE, Mar\u00e9chal V (2019) Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation. Antiviral Res 172:104615","journal-title":"Antiviral Res"},{"key":"9_CR204","doi-asserted-by":"crossref","unstructured":"Gresele P, Malvestiti M, Momi S (2018) Anti-platelet treatments in cancer: basic and clinical research. Thromb Res 164(Suppl 1):S106\u2013S111","DOI":"10.1016\/j.thromres.2017.12.016"},{"key":"9_CR205","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.apsb.2020.04.008","volume":"10","author":"X Liu","year":"2020","unstructured":"Liu X, Li Z, Liu S, Sun J, Chen Z, Jiang M, Zhang Q, Wei Y, Wang X, Huang YY et al (2020) Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B 10:1205\u20131215","journal-title":"Acta Pharm Sin B"},{"key":"9_CR206","doi-asserted-by":"publisher","DOI":"10.1038\/srep14972","volume":"5","author":"D Chen","year":"2015","unstructured":"Chen D, Cai J, Cheng J, Jing C, Yin J, Jiang J, Peng Z, Hao X (2015) Design, synthesis and structure-activity relationship optimization of lycorine derivatives for HCV inhibition. Sci Rep 5:14972","journal-title":"Sci Rep"},{"key":"9_CR207","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fcimb.2019.00277","volume":"9","author":"H Wang","year":"2019","unstructured":"Wang H, Guo T, Yang Y, Yu L, Pan X, Li Y (2019) Lycorine derivative LY-55 inhibits EV71 and CVA16 replication through downregulating autophagy. Front Cell Infect Microbiol 9:277","journal-title":"Front Cell Infect Microbiol"},{"key":"9_CR208","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/cmdc.201300505","volume":"9","author":"P Wang","year":"2014","unstructured":"Wang P, Li L-F, Wang Q-Y, Shang L-Q, Shi P-Y, Yin Z (2014) Anti-dengue-virus activity and structure-activity relationship studies of lycorine derivatives. Chem Med Chem 9:1522\u20131533","journal-title":"Chem Med Chem"},{"key":"9_CR209","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.7697","volume":"7","author":"L Yang","year":"2019","unstructured":"Yang L, Zhang JH, Zhang XL, Lao GJ, Su GM, Wang L, Li YL, Ye WC, He J (2019) Tandem mass tag-based quantitative proteomic analysis of lycorine treatment in highly pathogenic avian influenza H5N1 virus infection. PeerJ 7:e7697","journal-title":"PeerJ"},{"key":"9_CR210","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.antiviral.2005.02.007","volume":"67","author":"SY Li","year":"2005","unstructured":"Li SY, Chen C, Zhang HQ, Guo HY, Wang H, Wang L, Zhang X, Hua SN, Yu J, Xiao PG et al (2005) Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res 67:18\u201323","journal-title":"Antiviral Res"},{"key":"9_CR211","doi-asserted-by":"crossref","unstructured":"Shen L, Niu J, Wang C, Huang B, Wang W, Zhu N, Deng Y, Wang H, Ye F, Cen S, Tan W (2019) High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. J Virol 93:e00023-19","DOI":"10.1128\/JVI.00023-19"},{"key":"9_CR212","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1080\/22221751.2020.1772676","volume":"9","author":"YN Zhang","year":"2020","unstructured":"Zhang YN, Zhang QY, Li XD, Xiong J, Xiao SQ, Wang Z, Zhang ZR, Deng CL, Yang XL, Wei HP et al (2020) Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture. Emerg Microbes Infect 9:1170\u20131173","journal-title":"Emerg Microbes Infect"},{"key":"9_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 178:104787","journal-title":"Antiviral Res"},{"key":"9_CR214","doi-asserted-by":"crossref","unstructured":"Bray M, Rayner C, No\u00ebl F, Jans D, Wagstaff K (2020) Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors\u2019 responses. Antiviral Res 178:104805","DOI":"10.1016\/j.antiviral.2020.104805"},{"key":"9_CR215","doi-asserted-by":"crossref","unstructured":"Salgado-Benvindo C, Thaler M, Tas A, Ogando NS, Bredenbeek PJ, Ninaber DK, Wang Y, Hiemstra PS, Snijder EJ, van Hemert MJ (2020) Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle. Antimicrob Agents Chemother 64:e00900-20","DOI":"10.1128\/AAC.00900-20"},{"key":"9_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104873","volume":"181","author":"SY Kim","year":"2020","unstructured":"Kim SY, Jin W, Sood A, Montgomery DW, Grant OC, Fuster MM, Fu L, Dordick JS, Woods RJ, Zhang F, Linhardt RJ (2020) Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res 181:104873","journal-title":"Antiviral Res"},{"key":"9_CR217","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1021\/acsinfecdis.0c00522","volume":"6","author":"R Cao","year":"2020","unstructured":"Cao R, Hu H, Li Y, Wang X, Xu M, Liu J, Zhang H, Yan Y, Zhao L, Li W et al (2020) Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infect Dis 6:2524\u20132531","journal-title":"ACS Infect Dis"},{"key":"9_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104902","volume":"182","author":"M Okamoto","year":"2020","unstructured":"Okamoto M, Toyama M, Baba M (2020) The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 182:104902","journal-title":"Antiviral Res"},{"key":"9_CR219","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673\u2013683","journal-title":"Nat Rev Drug Discov"},{"key":"9_CR220","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","volume":"98","author":"L Men\u00e9ndez-Arias","year":"2013","unstructured":"Men\u00e9ndez-Arias L (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 98:93\u2013120","journal-title":"Antiviral Res"},{"key":"9_CR221","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tips.2007.10.013","volume":"29","author":"L Men\u00e9ndez-Arias","year":"2008","unstructured":"Men\u00e9ndez-Arias L, T\u00f6zs\u00e9r J (2008) HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol Sci 29:42\u201349","journal-title":"Trends Pharmacol Sci"},{"key":"9_CR222","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","volume":"318","author":"N Yamamoto","year":"2004","unstructured":"Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, Rabenau H, Doerr HW, Hunsmann G, Otaka A, Tamamura H, Fujii N, Yamamoto N (2004) HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 318:719\u2013725","journal-title":"Biochem Biophys Res Commun"},{"key":"9_CR223","doi-asserted-by":"crossref","unstructured":"Fintelman-Rodrigues N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, Ferreira AC, Mattos M, de Freitas CS, Cardoso Soares V, da Silva Gomes Dias S, Temerozo JR et al (2020) Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production. Antimicrob Agents Chemother 64:e00825-20","DOI":"10.1128\/AAC.00825-20"},{"key":"9_CR224","doi-asserted-by":"publisher","first-page":"5770","DOI":"10.1038\/s41467-019-13659-4","volume":"10","author":"NC Gassen","year":"2019","unstructured":"Gassen NC, Niemeyer D, Muth D, Corman VM, Martinelli S, Gassen A, Hafner K, Papies J, M\u00f6sbauer K, Zellner A et al (2019) SKP2 attenuates autophagy through beclin1-ubiquitination and its inhibition reduces MERS-coronavirus infection. Nat Commun 10:5770","journal-title":"Nat Commun"},{"key":"9_CR225","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/AAC.48.7.2693-2696.2004","volume":"48","author":"C-J Wu","year":"2004","unstructured":"Wu C-J, Jan J-T, Chen C-M, Hsieh H-P, Hwang D-R, Liu H-W, Liu C-Y, Huang H-W, Chen S-C, Hong C-F et al (2004) Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother 48:2693\u20132696","journal-title":"Antimicrob Agents Chemother"},{"key":"9_CR226","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","volume":"6","author":"J Xu","year":"2020","unstructured":"Xu J, Shi PY, Li H, Zhou J (2020) Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect Dis 6:909\u2013915","journal-title":"ACS Infect Dis"},{"key":"9_CR227","first-page":"25","volume":"2","author":"TJ Schaffner","year":"2009","unstructured":"Schaffner TJ, Skoner DP (2009) Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma. J Asthma Allergy 2:25\u201332","journal-title":"J Asthma Allergy"},{"key":"9_CR228","doi-asserted-by":"crossref","unstructured":"Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, Shimojima M, Fukushi S (2021) The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. J Virol 95:e01648-20","DOI":"10.1128\/JVI.01648-20"},{"key":"9_CR229","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.mayocp.2020.04.007","volume":"95","author":"K Nakajima","year":"2020","unstructured":"Nakajima K, Ogawa F, Sakai K, Uchiyama M, Oyama Y, Kato H, Takeuchi I (2020) A case of coronavirus disease 2019 treated with ciclesonide. Mayo Clin Proc 95:1296\u20131297","journal-title":"Mayo Clin Proc"},{"key":"9_CR230","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112739","volume":"207","author":"A Firth","year":"2020","unstructured":"Firth A, Prathapan P (2020) Azithromycin: the first broad-spectrum therapeutic. Eur J Med Chem 207:112739","journal-title":"Eur J Med Chem"},{"key":"9_CR231","doi-asserted-by":"publisher","unstructured":"Rosendaal FR (2020) Review of: \u201cHydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949\u201d. Int J Antimicrob Agents 56:106063","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"9_CR232","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1128\/JVI.00203-09","volume":"83","author":"EC Goodwin","year":"2009","unstructured":"Goodwin EC, Atwood WJ, DiMaio D (2009) High-throughput cell-based screen for chemicals that inhibit infection by simian virus 40 and human polyomaviruses. J Virol 83:5630\u20135639","journal-title":"J Virol"},{"key":"9_CR233","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2016-09-736892","volume":"129","author":"S Gayle","year":"2017","unstructured":"Gayle S, Landrette S, Beeharry N, Conrad C, Hernandez M, Beckett P, Ferguson SM, Mandelkern T, Zheng M, Xu T et al (2017) Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. Blood 129:1768\u20131778","journal-title":"Blood"},{"key":"9_CR234","doi-asserted-by":"publisher","first-page":"20803","DOI":"10.1073\/pnas.2007837117","volume":"117","author":"YL Kang","year":"2020","unstructured":"Kang YL, Chou YY, Rothlauf PW, Liu Z, Soh TK, Cureton D, Case JB, Chen RE, Diamond MS, Whelan SPJ, Kirchhausen T (2020) Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc Natl Acad Sci U S A 117:20803\u201320813","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR235","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1021\/acsinfecdis.0c00343","volume":"6","author":"S Saul","year":"2020","unstructured":"Saul S, Einav S (2020) Old drugs for a new virus: repurposed approaches for combating COVID-19. ACS Infect Dis 6:2304\u20132318","journal-title":"ACS Infect Dis"}],"container-title":["Advances in Experimental Medicine and Biology","Antiviral Drug Discovery and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-16-0267-2_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T03:05:50Z","timestamp":1675566350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-16-0267-2_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9789811602665","9789811602672"],"references-count":235,"URL":"https:\/\/doi.org\/10.1007\/978-981-16-0267-2_9","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"14 July 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}